Associate Scientist II/Scientist I

Fremont, Calif. – April 16, 2026. Alamar Biosciences, Inc. (“Alamar”), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the pricing of its upsized initial public offering of 11,250,000 shares of its common stock at a public offering price of $17.00 per share. In addition, Alamar has granted the underwriters a 30-day option to purchase up to an additional 1,687,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on April 17, 2026 under the ticker symbol “ALMR.” The gross proceeds from the offering are expected to be approximately $191.3 million, without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on April 20, 2026, subject to the satisfaction of customary closing conditions.

Fremont lab star Alamar races toward IPO after hiring blitz. Published on March 30, 2026 Fremont proteomics player Alamar Biosciences is making its move from quiet lab work to the public markets, filing to go public this week after a hiring blitz that added nearly 100 workers over the past two years. The company has been shifting from pure research to commercial sales, scaling its NULISA platform and rolling out larger multiplex panels for neurodegenerative and oncology research. Founder and CEO Yuling Luo, who has said a family death pushed her to pursue earlier cancer detection, is now steering the company through the paperwork for a public market debut. As reported by the San Francisco Business Times, Alamar filed a registration related to an initial public offering but has not yet revealed how much it intends to raise. The outlet also highlighted the rapid hiring spree and noted that the filing lands just as the company is working to scale its commercial footprint in the East Bay. Funding and product push. In February 2024, Alamar announced an oversubscribed 128 million dollar Series C round that brought total funding to nearly 250 million dollars and was pitched as fuel to speed up commercialization and expand its commercial teams. In its own release, Alamar Biosciences said the money would be used to grow sales and customer support operations as it ships its ARGO HT System and NULISA assays. The product pipeline has been busy, too. Last Tuesday, the company launched the NULISAseq Neuro 220 Panel, a 220-marker panel for Alzheimer's and Parkinson's research, according to a press release distributed via GlobeNewswire. The company is pitching it as its largest precision proteomics panel to date. Hiring and local impact. The San Francisco Business Times reported that Alamar added nearly 100 workers in the past two years as it scaled up manufacturing and commercial operations in Fremont. The company's LinkedIn page currently lists roughly 196 employees, underscoring how quickly its footprint has grown at its Fremont campus at 47071 Bayside Parkway. The Business Times tracked the recent headcount surge, while Alamar's LinkedIn page reflects the latest tally. What to watch next. The filing so far omits key details, such as timing and pricing, so investors, prospective customers, and employees will be watching for a full public SEC registration statement or follow-up disclosures. In recent releases, the company lists investor relations contacts and partnerships that highlight its pitch to pharmaceutical and academic partners. Both GlobeNewswire and Alamar Biosciences carry the company's most recent public statements and fundraising details.